| Liu, Yunjiang |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
NCT03580395: Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer |
|
|
| Enrolling by invitation | 2/3 | 200 | RoW | Apatinib, paclitaxel, cisplatin | Hebei Medical University Fourth Hospital | Breast Cancer | 07/22 | 12/22 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 350 | RoW | MRG002, Trastuzumab Emtansine for Injection | Shanghai Miracogen Inc. | Advanced Breast Cancer, Metastatic Breast Cancer | 09/23 | 10/23 | | |
NCT05004142: Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin |
|
|
| Recruiting | 2 | 70 | RoW | FCN-437c+Fulvestrant, FCN-437c+Letrozole+Goserelin | Ahon Pharmaceutical Co., Ltd., Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Affiliated Hospital of Hebei University | Breast Neoplasms | 12/21 | 06/23 | | |
NCT03728829: Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Trastuzumab+TP, Trastuzumab+Docetaxel+Carboplatin | Hebei Medical University Fourth Hospital, OrigiMed | Observational, Prospective | 10/22 | 12/22 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
NCT05114915: A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1b | 144 | RoW | Albumin-bound docetaxel | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 10/23 | 10/23 | | |
| Active, not recruiting | 1 | 297 | RoW | FS-1502 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Solid Tumor, Breast Cancer | 04/24 | 06/25 | | |
